An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries
Study Details
Study Description
Brief Summary
This is a multicenter, Phase 3, open-label, safety, tolerability, and characterization of pharmacokinetics study of the INL 001 (bupivacaine HCl) implant, at 300 mg, in patients following various soft-tissue surgeries: open ventral hernia repair, abdominoplasty, open abdominal hysterectomy, laparoscopic-assisted colectomy, and reduction mammoplasty.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
This is a multicenter, Phase 3, open-label, safety, tolerability, and characterization of pharmacokinetics study of the INL-001 (bupivacaine HCl) implant, at 300 mg, in patients following various soft-tissue surgeries: open ventral hernia repair, abdominoplasty, open abdominal hysterectomy, laparoscopic-assisted colectomy, and reduction mammoplasty. After a screening period, eligible patients will undergo study surgery under general anesthesia and have INL-001 implanted intraoperatively. Efficacy is also an exploratory measure in this study.
The study includes a screening period, an inpatient period (preoperative, intraoperative, postoperative) of approximately 5 days, and an outpatient follow-up period (up to 30 days after treatment). Posttreatment safety and/or efficacy assessments will be made throughout the study and as specifically scheduled through 96 hours posttreatment, on day 7 (telephone), on day 15 (clinic visit), and on day 30 (clinic visit). Unless the investigator determines further hospitalization is necessary, patients will be discharged approximately 96 hours posttreatment (inpatient day 5).
During the screening period, all patients will undergo eligibility and other screening and safety assessments. In addition, the investigator will administer the Pain Catastrophizing Scale (screening only) as an exploratory measure and the 15-item Quality of Recovery (QoR-15) questionnaire (baseline).
Adverse event and concomitant medication information, including use of rescue pain medication, will be collected throughout the study (inpatient and outpatient). Surgical wound healing/grading assessments and assessment for signs and symptoms potentially indicative of systemic bupivacaine toxicity will be made.
Blood samples for pharmacokinetic assessments will be collected from patients at multiple time points for the measurement of concentrations of bupivacaine in plasma.
After surgery, patient reports of pain intensity using an 11-point numeric pain rating scale (NPRS) will be recorded at multiple time points through 96 hours posttreatment. Patients will be permitted rescue medication (oral and/or intravenous) to manage breakthrough pain when it occurs. The QoR-15 questionnaire and Patient Global Assessment (for pain control) will be administered on an inpatient basis and on day 7. The Opioid Related Symptom Distress Scale will be administered on an inpatient basis.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: INL-001 (bupivacaine hydrochloride) implant INL-001 (bupivacaine hydrochloride) implant |
Combination Product: INL-001 (bupivacaine hydrochloride) implant
INL-001 (bupivacaine hydrochloride) implant
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Evaluate the safety and tolerability [Day 1 through Day 30]
The primary objective of the study is to evaluate the safety and tolerability of the INL-001 implant in patients. Measured by frequency and incidents of adverse events.
Secondary Outcome Measures
- Cmax [0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours]
Maximum (peak) plasma concentration
- Tmax [0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours]
Time to maximum (peak) plasma concentration
- Tlag [0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours]
Lag-time
- t½ Terminal Half life [0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours]
Terminal Half life
- λz [0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours]
Terminal phase rate constant
- AUC [0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours]
Area under the plasma concentration-time curve from Time 0 to last time of last quantifiable plasma concentration (AUC0-last)
- AUC0-∞ [0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours]
AUC from Time 0 to infinity
Other Outcome Measures
- SPI24 [0 to 24 hours]
Time-weighted sum of pain intensity from Time 0 through 24 hours (SPI24). Lower score has a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible". Minimum value would be "0" and Maximum value would be 240. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI24 = ∑[PI x (time t - time t-1)], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.
- SPI48 [0 to 48 hours]
Time-weighted sum of pain intensity from Time 0 through 48 hours (SPI48). Lower score has a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible". Minimum value would be "0" and Maximum value would be 480. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI48 = ∑[PI x (time t - time t-1)], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.
- SPI72 [0 to 72 Hours]
Time-weighted sum of pain intensity from Time 0 through 72 hours (SPI72) A lower score is a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible" Minimum value would be "0" and Maximum value would be 720. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI72 = ∑[PI x (time t - time t-1)], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.
- Total use of opioid rescue analgesia [0 to 24 hours postoperatively]
Total use of opioid rescue analgesia (mg equivalent) -higher score means more analgesia was needed and worse outcome
- Total use of opioid rescue analgesia [0 to 72 hours postoperatively]
Total use of opioid rescue analgesia (mg equivalent) -higher score means more analgesia was needed and worse outcome
- Total use of opioid rescue analgesia [0 to 48 hours postoperatively]
Total use of opioid rescue analgesia (mg equivalent) -higher score means more analgesia was needed and worse outcome
- Time to discharge from the postanesthesia care unit (PACU) [Immediately after the intervention/procedure/surgery]
Time to discharge from the PACU
- Opioid-related Symptom Distress Scale (OR-SDS) [24, 48, 72, and 96 hours posttreatment]
The OR-SDS is a measurement tool to assess patient experience following opioid use in the postoperative setting.
- 15-item Quality of Recovery (QoR-15) Questionnaire [24, 48, 72, and 96 hours, and day 7 posttreatment]
The 15-item Quality of Recovery (QoR-15) Questionnaire s a surgical recovery assessment tool. The QoR-15 assesses postsurgical recovery from the patient's perspective and incorporates all 5 dimensions of health patient support, comfort, emotions, physical independence, and pain. Investigator judgement will be used to determine if a positive finding on the QoR-15 is clinically significant and reportable as an adverse event.
- Patient Global Assessment (PGA) as Related to Postoperative Pain [24, 48, 72, and 96 hours, and day 7 posttreatment]
The PGA will be administered by study staff who ask patients to rate "how well your pain has been controlled during the study" on a 5 point nominal scale: 0-poor, 1-fair, 2-good, 3-ery good, or 4-excellent.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Has a body mass index of 18-35 kg/m2.
-
Has a planned (nonemergency) open ventral hernia repair, abdominoplasty (with rectus sheath plication, in the opinion of the surgeon), open abdominal hysterectomy, laparoscopic-assisted colectomy, or reduction mammoplasty to be conducted using standard surgical technique under general anesthesia.
-
Has the ability and willingness to comply with all study procedures including being domiciled for at least 96 hours after surgery.
-
Is willing to use opioid analgesia, if needed.
Exclusion Criteria:
-
Has a known hypersensitivity to amide-type local anesthetics, fentanyl, morphine, oxycodone, acetaminophen, NSAIDs, or bovine products.
-
Is scheduled for other significant concurrent surgical procedures (eg, cholecystectomy or additional cosmetic procedures concurrent with abdominoplasty).
-
Has used an opioid analgesic on an extended daily basis (≥5 mg oral morphine equivalents per day for 3 or more days a week) within 4 weeks before surgery and/or chronically uses pain medication.
-
Has any chronic painful condition (eg, fibromyalgia), as determined by the investigator, that may confound the assessment of pain associated with the study surgery.
-
For open hernia repair, has open ventral hernia with primary suture repair and mesh placement requiring an incisional length greater than 12 cm.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Helen Keller Hospital | Sheffield | Alabama | United States | 35660 |
| 2 | Lotus Clinical Research | Pasadena | California | United States | 91105 |
| 3 | Midwest Clinical Research | Dayton | Ohio | United States | 45417 |
| 4 | Daneshvari Solanki | Houston | Texas | United States | 77004 |
| 5 | Baylor College of Medicine | Houston | Texas | United States | 77030 |
| 6 | Memorial Hermann | Houston | Texas | United States | 77089 |
| 7 | Endeavor Clinical Trials | San Antonio | Texas | United States | 78229 |
Sponsors and Collaborators
- Innocoll
Investigators
- Study Director: Anne Arriaga, Lotus Clinical Research
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- INN-CB-025